The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban

References

• Douxfils J, Tamigniau A, Chatelain B, et al. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J. 2014;12:24–40.
   PubMedGoogle Scholar
• Adcock DM, Gosselin R. Direct Oral Anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res. 2015;136:7–12.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412–421.
   PubMed Web of Science ®Google Scholar
• Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor–in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203–216.
   PubMed Web of Science ®Google Scholar
• Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med. 2015;53:185–197.
   PubMed Web of Science ®Google Scholar
• Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815–825.
   PubMed Web of Science ®Google Scholar
• Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104:1078–1079.
   PubMed Web of Science ®Google Scholar
• Tripodi A. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost. 2013;11:576–578.
   PubMed Web of Science ®Google Scholar
• Jackson LR. 2nd and Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis. 2014;37:380–391.
   PubMed Web of Science ®Google Scholar
• Baglin T, Keeling D, Kitchen S, British Committee for Standards in H. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2012;159:427–429.
   PubMed Web of Science ®Google Scholar
• Samama MM, Contant G, Spiro TE, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost. 2012;18:150–158.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Chantarangkul V, Guinet C, et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011;9:226–228.
   PubMed Web of Science ®Google Scholar
• Harenberg J, Marx S, Kramer R, et al. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis. 2011;22:637–641.
   PubMed Web of Science ®Google Scholar
• Dale BJ, Ginsberg JS, Johnston M, et al. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost. 2014;12:1810–1815.
   PubMed Web of Science ®Google Scholar
• Ratzinger F, Schmetterer KG, Haslacher H, et al. Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories. Clin Chem Lab Med. 2014;52:1193–1202.
   PubMed Web of Science ®Google Scholar
• Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49:761–772.
   PubMed Web of Science ®Google Scholar
• Van den Besselaar AM, Barrowcliffe TW, Houbouyan-Reveillard LL, et al. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost. 2004;2:1946–1953.
   PubMed Web of Science ®Google Scholar
• Adcock DM, Johnston M. Evaluation of frozen plasma calibrants for enhanced standardization of the international normalized ratio (INR): a multi-center study. Thromb Haemost. 2002;87:74–79.
   PubMed Web of Science ®Google Scholar
• Solvik UO, Petersen PH, Monsen G, et al. Discrepancies in international normalized ratio results between instruments: a model to split the variation into subcomponents. Clin Chem. 2010;56:1618–1626.
   PubMed Web of Science ®Google Scholar
• Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis. 2016;41:241–247.
   PubMed Web of Science ®Google Scholar
• Chin PK. Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants? Semin Thromb Hemost. 2015;41:195–207.
   PubMed Web of Science ®Google Scholar
• Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128–1139.
   PubMed Web of Science ®Google Scholar
• Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172:315–316.
   PubMed Web of Science ®Google Scholar
• Gosselin RC, Adcock D, Hawes EM, et al. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb Haemost. 2015;113:77–84.
   PubMed Web of Science ®Google Scholar
• Lippi G, Ardissino D, Quintavalla R, et al. Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. J Thromb Thrombolysis. 2014;38:269–274.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012;130:956–966.
   PubMed Web of Science ®Google Scholar
• Rathbun S, Tafur A, Grant R, et al. Comparison of methods to determine rivaroxaban anti-factor Xa activity. Thromb Res. 2015;135:394–397.
   PubMed Web of Science ®Google Scholar
• Harenberg J, Marx S, Weiss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012;10:1433–1436.
   PubMedGoogle Scholar
• Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379–387.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qian Q, Qian G, et al. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk. Br J Biomed Sci. 2016;73:134–139.
   PubMed Web of Science ®Google Scholar
• van Veen JJ, Smith J, Kitchen S, et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol. 2013;160:859–861.
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Ansell J, Spiro T, et al. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med. 2013;45:423–429.
   PubMed Web of Science ®Google Scholar